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Summary
Objectives: The objective of this study was to evaluate clinical and microbiological character-
istics of Chagas disease (ChD) with central nervous system (CNS) involvement in AIDS patients.
Methods: This was a retrospective study of clinical and laboratory findings of HIV-infected
patients with a confirmed diagnosis of ChD involving the CNS during the period 1992—2007 at
the ‘‘Francisco J. Mun˜iz’’ Infectious Diseases Hospital, Buenos Aires, Argentina.
Results: Of a total of 15 patients, 14 were male and the median age was 33 years (range 25—54
years). Seven out of nine had lived in a Chagas endemic area and 7/10 were intravenous drug users
(IDUs). The disease was reactivated during corticosteroid therapy in three patients. Clinical
manifestations were: headache (11/15), focal neurological deficits (9/15), fever (9/15), menin-
gismus (7/15), seizures (7/15), alteredmental status (5/15), and cardiac involvement (3/10). The
median CD4 T-cell count at the time of reactivation was 64 cells/ml (range 1—240). Twelve of 14
had positive serology for Trypanosoma cruzi; the two negative were IDUs. Cerebrospinal fluid
(CSF) findings (median (range)): cell count 5/mm3 (2—90), protein level 0.68 g/l (0.1—1.84), and
glucose level 0.45 g/l (0.13—0.73). CSF direct examination for T. cruzi was positive in 11/13.
Neuroimaging findings showed a single hypodense lesion in 7/14 and normal images in 2/14.
Twelve patients were treated with benznidazole. The global mortality was 79% (11/14).
Conclusions: ChD reactivation should be considered as a differential diagnosis of meningoence-
phalitis in HIV patients with low CD4 T-cell counts, previous residency in an endemic area, and/or
IDUs. Whenever possible, lumbar puncture should be performed because of the high accuracy for
early diagnosis.
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Chagas disease, or American trypanosomiasis, is a zoonotic
disease caused by Trypanosoma cruzi, a flagellated proto-
zoan. It extends from the southern USA to the south of South
America. T. cruzi is transmittedmainly by vectors (triatomine
bugs) more common in rural areas. Other mechanisms of
transmission are transfusion of infected blood, transplacen-
tal route, organ transplantation from an infected donor and,
more rarely, oral route and laboratory accidents.1 Sharing
intravenous needles with an infected person is another pos-
sible means of transmission.2,3
In Latin America, the disease affects about 25% of the
population, with 16 to 18 million people infected and about
100 million at high risk of infection.4 Following urban migra-
tion, Chagas disease has become a health problem in non-
endemic cities and countries.1,5 In the USA, approximately
50 000 to 100 000 immigrants have evidence of chronic T.
cruzi infection,6 and the estimated seroprevalence is one in
4655 blood donations for T. cruzi antibodies.7 In recent years
many non-vector-associated cases have been diagnosed in
the USA, Canada, and Europe.3,8
Three phases are described for this disease. The acute
phase is typically asymptomatic or with mild symptoms such
as fever, malaise, swelling at the site of inoculation, and
lymphadenopathy. Severe myocarditis and meningoencepha-
litis can also occur in a small proportion of patients. The
acute phase usually resolves spontaneously in 2—4 months.
Following this, the indeterminate phase is established. This
asymptomatic period of clinical latency can last years or
throughout life. However, in approximately 30% of patients,
signs of cardiopathy and/or megaesophagus/megacolon
develop years or decades after the first infection. This is
called chronic symptomatic Chagas disease.1,9,10
Chagas disease reactivation is associated with states of
immunodeficiency, such as hematological malignancies, kid-
ney or heart transplantation, or corticosteroid therapy.7 In
patients with AIDS this reactivation has a high mortality rate,
and it presents with neurological compromise (brain mass
lesions or acute diffuse meningoencephalitis) in 75—90% of
these patients;11 acute myocarditis is found in 44% of
patients.9 Other uncommon presentations including skin
lesions,12 peritonitis,13 and cervicitis14 have been described.
Since the first reported case of Chagas disease reactiva-
tion in an HIV-infected patient,15 many cases have been
published in the literature, most of them from Latin America,
though some cases have been reported in non-endemic
countries.3,16 However, limited data from prospective and
retrospective studies of reactivations involving the central
nervous system (CNS) are available. The aim of this study was
to evaluate clinical and microbiological characteristics of 15
HIV-infected patients with a confirmed diagnosis of Chagas
disease reactivation with CNS involvement.
Methods
This was a retrospective study of clinical and laboratory
findings for 15 HIV-infected patients with a confirmed diag-
nosis of Chagas disease involving the CNS, for the period
1992—2007, at the ‘‘Francisco J. Mun˜iz’’ Infectious Diseases
Hospital, Buenos Aires, Argentina. Data recorded includedepidemiological information, clinical findings, time from the
onset of symptoms to diagnosis, serological and direct micro-
scopic examination (DME) tests for Trypanosoma cruzi infec-
tion, neuroimaging findings, CD4 cell count, cerebrospinal
fluid (CSF) examination, treatment, and clinical outcome.
Screening for HIV infection was done by ELISA; positive
results were confirmed byWestern blot. Serological diagnosis
of T. cruzi infection was defined as at least two different
positive serological tests (indirect immunofluorescence
assay, indirect hemagglutination assay, ELISA, complement
fixation for anti-T. cruzi antibodies). Detection of parasites
was done by Strout method17 in blood and by direct micro-
scopic examination and Giemsa-stained smear in CSF.
CNS Chagas disease was defined as the detection of: (1) T.
cruzi trypomastigote forms through DME of CSF; (2) amasti-
gote forms in histologic examination of brain tissue; (3)
trypomastigote forms through DME of blood, with neurolo-
gical manifestations and clinical response to treatment with-
out another concomitant neurological disease.
Results
Of a total of 15 patients, 14 weremen; themedian age was 33
years (range 25—54 years). Ten out of fifteen were aware of
their previous HIV seropositive status and 6/15 had a con-
comitant opportunistic infection (OI; category C of the CDC
classification) at admission. None of them were receiving
highly active antiretroviral therapy (HAART) and only three
were under co-trimoxazole prophylaxis. In only 4/15 had the
diagnosis of T. cruzi infection been done before admission.
Seven out of nine had lived in a Chagas endemic area. Seven
out of ten were intravenous drug users (IDUs) and in three
patients this was the only risk factor for T. cruzi infection. In
three patients the disease was reactivated while they were
receiving high dose corticosteroid therapy (prednisone
equivalent 20 mg/day or higher for more than 21 days) for
another OI (Pneumocystis jirovecii pneumonia, Toxoplasma
encephalitis, and oral plasmablastic lymphoma).
The main clinical manifestations are shown in Table 1 and
were: headache (11/15), focal neurological deficits (9/15),
fever (9/15), meningismus (7/15), seizures (7/15), altered
mental status (5/15), and concomitant cardiac involvement
(3/10). The median CD4 T-cell count at the time of Chagas
disease reactivation was 64 cells/ml (range 1—240); 77% of
the patients had a count of <100 CD4 T-cells/ml. Twelve out
of fourteen had positive serological tests for T. cruzi infec-
tion; the two who were negative were IDUs. T. cruzi para-
sitemia was detected in only 1/7.
Lumbar puncture was performed in 13 patients. In the
other two patients this diagnostic procedure was contra-
indicated. CSF findings were (median (range)): cell count
5/mm3 (2—90), protein level 0.68 g/l (0.1—1.84), and glu-
cose level 0.45 g/l (0.13—0.73). One of the patients had
normal CSF values. CSF direct examination for T. cruzi was
positive in 11/13 (85%) (Figure 1).
Neuroimaging studies were performed in 14 patients.
The most frequent finding was a single supratentorial hypo-
dense lesion (50%) compatible with abscess, involving pre-
dominantly the white matter of the brain lobes (83%)
(Figure 2). Two patients had normal neuroimaging studies
(14%) (Table 2).
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Table 1 Clinical manifestations in HIV positive patients with a
confirmed diagnosis of Chagas disease involving the central
nervous system
n %
Headache 11/15 73
Focal neurological deficits 9/15 60
Fever 9/15 60
Meningismus 7/15 47
Seizures 7/15 47
Altered mental statusa 5/15 33
Concomitant cardiac involvementb 3/10 30
a Includes confusion, delirium, or a declining level of consciousness
ranging from lethargy to coma.
b Includes signs and symptoms of acute myocarditis evaluated with
electrocardiogram and echocardiogram without a history of previous
cardiomyopathy. Not confirmed by isolation of parasites in heart
tissue.
Figure 2 Magnetic resonance imaging showing a single peri-
ventricular white matter lesion, with gadolinium enhancement
and perilesional edema corresponding with cerebral chagoma.
Figure 1 Trypanosoma cruzi trypomastigote in a smear of
cerebrospinal fluid (Giemsa).
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Table 3 Benznidazole side effects in 12 patients with central
nervous system Chagas disease
n %
Hematological a 3 25
Rash 2 17
Gastrointestinal b 1 8
Peripheral neuropathy 1 8
None 6 50
a Thrombocytopenia, anemia, or agranulocytosis.
b Anorexia, nausea, vomiting, or abdominal pain.
Figure 3 Chagasic necrotizing encephalitis with amastigotes
of Trypanosoma cruzi.Diagnosis was achieved by DME of CSF in 11/15, by stereo-
tactic brain biopsy and histologic examination of smear
tissues in 3/15 (Figure 3), and by Strout method in 1/15.
The median time between the onset of clinical manifesta-
tions and diagnosis was 15 days (range 1—60). Twelve out of
15 patients were treated with oral benznidazole (5 mg/kg/
day divided into two daily doses), six of whom (50%) experi-
enced side effects during hospitalization (Table 3). Three
patients had not received specific treatment; in two of them
diagnosis was done postmortem, and the other was dis-
charged after diagnosis with no follow-up data available.
Eleven of fourteen died (79%) with a median time of
survival of 21 days (range 0—180). Of the survivors, one
was discharged and followed up at another center and infor-
mation on his outcome was not available. The other two
survivors continued on secondary prophylaxis with benznida-
zole 200 mg three times a week and were started on anti-
retroviral therapy. In one of them the secondary prophylaxis
was interrupted after immune reconstitution without any
relapse of T. cruzi infection to date.11
Discussion
To the best of our knowledge, this is one of the largest
reported series of HIV-infected patients with neurological
involvement due to Chagas disease. History of living in an
endemic area is still the major risk factor for T. cruzi trans-
mission. However, we should not rule out the diagnosis of
Chagas disease in the absence of this precedent. Sharing an
intravenous needle is a newmeans of urban transmission of T.
cruzi infection.2,3 In our study, one of the patients hadpositive serological tests for T. cruzi at admission, but 14
years previously he had had a negative one. He had never
been in an endemic area or been transfused, and therewas no
family history of the disease. Sharing intravenous needles
was the only risk factor present, which suggests that in this
case the infection was acquired by this route.
Positive serological tests for T. cruziwere present in 12 out
of 14 patients (86%). Therefore, the absence of T. cruzi
antibodies makes a diagnosis of Chagas disease unlikely. In
our series the only two patients with negative tests were
IDUs. Reviewing the literature, of five cases of Chagas disease
reactivation with negative serological tests, four had as the
possible means of transmission the sharing of intravenous
needles.2,18,19 This association may be related to the time at
which the infection was acquired, probably when there was
profound immunosuppression due to HIV. In this context, the
humoral response cannot occur properly.20 Serology should
not be relevant in the diagnosis of Chagas disease in these
cases.2
Lumbar puncture had a high sensitivity for diagnosis in our
study (85%), hence this procedure should always be per-
formed in the absence of contraindications to it. The high
frequency of trypomastigote forms in CSF could be explained
histologically by the presence of inflammation and amasti-
gote forms in the leptomeninges in patients with chagasic
meningoencephalitis.21 HIV infection leads to a significant
exacerbation of T. cruzi parasitemia in patients with chronic
Chagas disease.22 Parasitemia detected by DME may precede
the clinical manifestations or be detected later.23 However,
positive blood cultures or xenodiagnostic tests for T. cruzi
should not be interpreted as evidence of reactivation since
they are positive in the majority of the patients with chronic
Chagas disease.9 In our study T. cruzi parasitemia was
detected in 1/7. The small number of patients in which
the Strout method was performed is explained in part by
the fact that if the diagnosis was first achieved by DME of CSF,
no further examinations were done. The low accuracy of the
Strout method in our study in comparison with the literature9
can be explained by the fact that serial samples were not
examined for all patients; this is necessary to increase the
sensitivity of this test.
Among the patients in our series, headache, focal neuro-
logical deficits, and fever were the most common manifesta-
tions of CNS involvement, indistinguishable from other
causes of meningoencephalitis, like toxoplasmosis. Cardiac
involvement is another form of Chagas disease reactivation in
AIDS patients. It presents alone (19%) or associated with CNS
involvement (25%).9 Similar to the literature, in our study 30%
of the patients for whom systematic electrocardiograms and
echocardiograms were performed had cardiac involvement.
The patients who had cardiac involvement had a longer time
to diagnosis when compared to the patients who had only CNS
involvement (median time between onset of clinical symp-
toms and diagnosis: 28 days versus 3 days). It is probable that
cardiac involvement appears later in the natural evolution of
the reactivation, but more studies must be done to confirm
this theory.
All patients but two had abnormal neuroimages. As has
already been pointed out, the most frequent finding was a
single supratentorial hypodense lesion compatible with
abscess, predominantly involving the white matter of the
brain. This is similar to findings reported in the literature.24 In
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a supratentorial compromise. The imaging pattern of the
brain is similar to that found in cerebral toxoplasmosis in
which involvement of the thalamus and basal ganglia is more
common.9 In our study, only two (17%) had this location.
Normal neuroimages cannot rule out the diagnosis of CNS
involvement since there are cases without pathological
images (two cases in our series; 17%).
There is evidence that the use of corticosteroid therapy in
patients with serological evidence of Chagas disease increases
the risk of reactivation and the intensity and the frequency of
T. cruzi parasitemia. However, there are few reports of
clinical reactivations in these patients.25 Most have shown
an association with the use of another immunosuppressive
drug or another concomitant disease such as lymphoma or
leukemia.26 The role of primary prophylaxis with benznida-
zole is uncertain and controversial in these patients.26,27
There are no reports in the literature of Chagas disease
reactivations associated with the use of corticosteroid ther-
apy and AIDS. In three patients in our series, reactivation of
their disease occurred while they were receiving corticoster-
oid therapy for another OI or neoplasm. One of these patients
was admitted with the diagnosis of meningoencephalitis; he
had positive serological tests for Toxoplasma gondii and T.
cruzi. DME for T. cruzi in blood and CSF were negative.
Empirical treatment for Toxoplasma encephalitis was started
and corticosteroid therapy was added for mass effect. After
neurological and radiological improvement and still under
corticosteroid therapy he presented a contralateral neurolo-
gical deficit. Neuroimages showed the presence of new
lesions, and CSF direct examination showed trypomastigote
forms of T. cruzi. Treatment with benznidazole was started
with clinical and radiological improvement. The positive
serological test for T. gondii, response to anti-Toxoplasma
therapy, and initial negative DME for T. cruzi, suggest that
Chagas disease reactivation could have been caused by the
high dose of corticosteroid therapy the patient received.
Only two drugs are effective for the treatment of patients
with Chagas disease, nifurtimox and benznidazole.1,28 The
main limitations of these drugs are that only oral formula-
tions are available and the high frequency of adverse side
effects. Limited data are available on the efficacy of these
agents in patients with AIDS and Chagas disease reactivation.
In the present series all patients were treated with benzni-
dazole; 50% experienced side effects, most of them hema-
tological disorders. Secondary prophylaxis with benznidazole
(5 mg/kg three times a week) is recommended.29 Two of our
patients continued under secondary prophylaxis with no
relapses of the disease. In one of them, secondary prophy-
laxis was interrupted after immune reconstitution, with no
reactivations after 5 years.
The global mortality in our study was 79% with a median
time of survival of 21 days. This high mortality rate may be
related with the delayed diagnosis (median 18 days). This
could be associated to the clinical and radiographic simila-
rities to Toxoplasma encephalitis and to the low index of
suspicion. Another explanation for the high mortality rate
could be the profound immunosuppression in these patients.
All but one had <200 CD4 T-cells/ml and 77% of the patients
had <100 CD4 T-cells/ml. The high prevalence of concomi-
tant OIs at admission could be another reason for the high
mortality rate in our series.In conclusion Chagas disease reactivation is associated
with a high mortality rate in patients with AIDS, probably
related to delayed diagnosis and profound immunosuppres-
sion. It should be considered as a differential diagnosis of
meningoencephalitis in HIV patients with very low CD4 T-cell
counts, previous residency in an endemic area, and/or IDUs.
A positive serological test is relevant to the diagnosis of T.
cruzi infection, however the absence of T. cruzi antibodies
cannot rule out the diagnosis, especially in IDUs.
Corticosteroid therapy should be used with caution
since they could promote a reactivation of T. cruzi infec-
tion in these patients. Because of this, in our opinion, all
patients with AIDS and Chagas disease undergoing high
corticosteroid therapy or therapy with another immuno-
suppressive drug, should routinely undergo DME for T. cruzi
in order to prevent reactivations. Whenever possible,
lumbar puncture should be performed because of the high
accuracy for early diagnosis. All patients should be system-
atically evaluated for cardiac involvement. Finally, we
think that early diagnosis followed by specific treatment,
immune reconstitution associated with HAART, and second-
ary prophylaxis, should improve the poor prognosis in these
patients.
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